| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
SL Science Holding Limited Ordinary Shares
$2.67
-0.16 (-5.65%)
Market Cap
1.50 B
EPS
-
P/E Ratio
-
Value Trade
174.91 K
-4.64 %
Week
-38.34 %
1 Month
-19.82 %
3 Month
-19.82 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
45.93 K
52 Week Range
-
% held by Insiders
59.54 %
% held by Institutions
-
Enterprise Value
-
Total Shares
560.34 M
Short %
0.05 %
Float Shares
226.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for SL Science Holding Limited Ordinary Shares
4Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
◆Oral PresentationVdelta2Presentation
Subscribe to view catalyst details
TBD
▲Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-12 | Vdelta2+ Gamma Delta T Cells | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-07-12 | Vdelta2+ Gamma Delta T Cells | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-07-12 | Vdelta2+ Gamma Delta T Cells | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLBT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLBT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SLBT
Aug 12, 2026▼ -5.6%today
A New Framework for Developing γδ T Cell Therapy in Glioblastoma
SL Science has published a new framework for developing γδ T cell therapy targeting glioblastoma, a challenging brain cancer. The paper emphasizes the need for innovative trial designs that incorporate realistic conditions and effective delivery methods. The authors advocate for rigorous evidence generation in human trials to improve treatment outcomes. This independent review aims to set a high standard for future clinical programs.
Read more →-SLBT
Aug 12, 2026▼ -5.6%today
現成型細胞治療的新可能——γδ T細胞對抗膠質母細胞瘤
SL Science has co-authored a peer-reviewed framework for the clinical development of T-cell therapy targeting glioblastoma. This collaboration with researchers from Taiwan aims to address the challenges in treating this aggressive cancer. The study emphasizes the need for early-stage testing and effective measurement of therapeutic efficacy in real-world settings. The framework is expected to guide future clinical trials and improve patient outcomes.
Read more →-SLBT
Jul 20, 2026▼ -8.6%on this news· ran to -26% by day 3
SL Science 於 2026 世界基礎與臨床藥理學大會成功 (WCP 2026) 展示腦癌突破性療法研究成果
SL Science Holding Limited announced a successful exhibition of its breakthrough brain cancer therapy research at the 2026 World Congress of Basic and Clinical Pharmacology. The company collaborated with leading academic institutions to present findings on gamma delta T cell therapy, which shows promise in treating glioblastoma. This event highlights the company's commitment to advancing cancer treatment technologies.
Read more →-SLBT
Jul 17, 2026SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
SL Science showcased groundbreaking research on glioblastoma treatment at the 2026 World Congress of Basic and Clinical Pharmacology. The study demonstrated the effectiveness of gamma delta T cells in eliminating tumors in preclinical models. Key highlights included complete tumor eradication and a favorable safety profile, emphasizing the potential of this innovative therapy.
Read more →-SLBT
Jul 11, 2026▼ -8.5%on this news
SL Science Holding Limited 就 GDT 細胞治療腦癌適應症向美國 FDA 提交孤兒藥資格認定申請
SL Science Holding Limited has announced the submission of an orphan drug designation request for its Gamma Delta T cell therapy, Vdelta2+, targeting glioblastoma multiforme. This submission has been formally accepted by the FDA, indicating progress in the development of this innovative treatment. The company is set to present its findings at the upcoming World Congress on Precision Medicine.
Read more →-SLBT
Jul 10, 2026SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
SL Science Holding Limited has submitted an Orphan Drug Designation request to the FDA for its GDT cell therapy targeting glioblastoma multiforme. This submission acknowledges the critical unmet medical need in treating this aggressive brain cancer. The therapy's unique mechanism allows it to engage tumor cells directly, potentially improving treatment outcomes. The company aims to advance its GDT platform towards clinical development.
Read more →-SLBT
Jun 19, 2026▼ -21.9%on this news
SL Science Holding Limited Reports Full Year 2025 Financial Results
SL Science Holding Limited has reported its full year 2025 financial results, highlighting progress in its Gamma Delta T Cell and CD-19 Armed-T therapy platforms. The company is focused on expanding its oncology pipeline and enhancing its clinical development capabilities. Additionally, SL Science aims to accelerate its global growth following its recent Nasdaq listing.
Read more →-SLBT
Jun 19, 2026▼ -21.9%on this newsshared move
SL Science Holding Limited 公布 2025 全年財報
SL Science Holding Limited (SLBT) announced its financial results for 2025, highlighting a focus on innovative therapies and significant investments in research and development. The company aims to advance its clinical pipeline, particularly in the area of gamma delta T-cell therapies. Despite a projected revenue decline in 2024, management remains optimistic about future growth and market opportunities. The firm has successfully completed funding rounds to support its strategic initiatives.
Read more →-SLBT
Jun 15, 2026前身為 SL BIO Ltd. 的 SL Science Holding Limited 完成業務合併，正式登錄 Nasdaq 全球市場
SL Science Holding Limited, previously SL BIO Ltd., has successfully completed its business combination with Horizon Space Acquisition II Corp. and is now officially listed on the Nasdaq Global Market under the ticker SLBT. The merger, which was finalized on June 15, 2026, includes substantial investment support totaling $780 million, aimed at advancing SL Science's innovative Gamma Delta T cell therapies.
Read more →-SLBT
Jun 14, 2026SL Science Holding Limited Completes Business Combination and Lists on the Nasdaq Global Market (Formerly known as SL BIO Ltd.)
SL Science Holding Limited, previously known as SL BIO Ltd., has successfully completed its business combination and is now trading on the Nasdaq Global Market as SLBT. The company focuses on developing allogeneic GDT cell-based therapies aimed at treating pancreatic cancer and glioblastoma. This advancement marks a significant step in their therapeutic offerings.
Read more →-SLBT
Jun 12, 2026SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
SL BIO Ltd. has successfully closed its business combination with Horizon Space Acquisition II, transitioning to a publicly traded entity under the new Nasdaq ticker SLBT. This merger, valued at approximately $5.568 billion, includes a $7.8 million PIPE financing aimed at accelerating the company's growth. SL Bio specializes in innovative cellular and gene therapies, with a plan to scale cell therapy into a more standardized and globally applicable model. The company's leadership is backed by an experienced board, positioned to guide its future initiatives in the biopharmaceutical sector.
Read more →Competitive Position
How SLBT ranks across every disease it competes inCompetitive Position is a premium feature
See how SLBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial